Sex, drugs and gender roles: mapping the use of sex and gender based analysis in pharmaceutical policy research

[1]  V. Runnels,et al.  Appraising the evidence: applying sex- and gender-based analysis (SGBA) to Cochrane systematic reviews on cardiovascular diseases. , 2010, Journal of women's health.

[2]  D. Gould,et al.  What are scoping studies? A review of the nursing literature. , 2009, International journal of nursing studies.

[3]  S. Morgan,et al.  Chronic catastrophes: exploring the concentration and sustained nature of ambulatory prescription drug expenditures in the population of British Columbia, Canada. , 2009, Social science & medicine.

[4]  O. Helve,et al.  Effect of legislative changes in drug promotion on medical students: questionnaire survey , 2008, Medical education.

[5]  J. Erdman,et al.  Medication abortion in Canada: a right-to-health perspective. , 2008, American journal of public health.

[6]  H. Delemarre-van de Waal,et al.  The treatment of adolescent transsexuals: changing insights. , 2008, The journal of sexual medicine.

[7]  J. Lexchin.  Clinical Trials in Canada: Whose Interests are Paramount? , 2008, International journal of health services : planning, administration, evaluation.

[8]  D. Molyneux.  Combating the "other diseases" of MDG 6: changing the paradigm to achieve equity and poverty reduction? , 2008, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[9]  Daniel M. Hartung,et al.  Impact of a Medicaid Copayment Policy on Prescription Drug and Health Services Utilization in a Fee-for-Service Medicaid Population , 2008, Medical care.

[10]  C. Varcoe,et al.  Women's Health in Canada: Critical Perspectives on Theory and Policy , 2008 .

[11]  R. Ferner,et al.  Over the counter medicines: proceed with caution , 2008, BMJ : British Medical Journal.

[12]  T. Milewa.  Representation and legitimacy in health policy formulation at a national level: perspectives from a study of health technology eligibility procedures in the United Kingdom. , 2008, Health policy.

[13]  Praveen Kumar,et al.  Medication use in the neonatal intensive care unit: current patterns and off-label use of parenteral medications. , 2008, The Journal of pediatrics.

[14]  S. Morgan,et al.  The effect of evidence-based drug coverage policies on pharmaceutical r&d: a case study from british columbia. , 2008, Healthcare policy = Politiques de sante.

[15]  R. Levine,et al.  Patients’ Understanding of the Regulation of Dietary Supplements , 2008, Journal of Community Health.

[16]  J. Gurwitz,et al.  Patients At-Risk for Cost-Related Medication Nonadherence: A Review of the Literature , 2007, Journal of General Internal Medicine.

[17]  Nicholas C. Ide,et al.  Trial Registration at ClinicalTrials.gov between May and October 2005. , 2005, The New England journal of medicine.

[18]  S. Morgan,et al.  Medicine by media: Did a critical television documentary affect the prescribing of cyproterone– estradiol (Diane-35)? , 2005, Canadian Medical Association Journal.

[19]  D. Young.  Our Bodies, Ourselves A New Edition for a New Era , 2005 .

[20]  H. Arksey,et al.  Scoping studies: towards a methodological framework , 2005 .

[21]  M. Boscoe,et al.  The Women's Health Movement: Looking Back and Moving Forward , 2004 .

[22]  S. M. Johnson,et al.  Assessment of analysis by gender in the Cochrane reviews as related to treatment of cardiovascular disease. , 2003, Journal of women's health.

[23]  Troyen A. Brennan,et al.  No-fault compensation for medical injuries: the prospect for error prevention. , 2001, JAMA.

[24]  C. Meinert,et al.  The inclusion of women in clinical trials , 1995, Science.

[25]  E M Rogers,et al.  The Origins and Development of the Diffusion of Innovations Paradigm as an Example of Scientific Growth , 1995, Science communication.

[26]  S. Morgan,et al.  Cost-related prescription nonadherence in the United States and Canada: a system-level comparison using the 2007 International Health Policy Survey in Seven Countries. , 2009, Clinical therapeutics.

[27]  S. Abdulla,et al.  Challenges of establishing a Community Advisory Board (CAB) in a low-income, low-resource setting: experiences from Bagamoyo, Tanzania , 2009, Health research policy and systems.

[28]  U. Gerdtham,et al.  International Journal for Equity in Health Health Financing for the Poor Produces Promising Short-term Effects on Utilization and Out-of-pocket Expenditure: Evidence from Vietnam , 2009 .

[29]  Michael E. Furrow.  Pharmaceutical patent life-cycle management after KSR v. Teleflex. , 2008, Food and drug law journal.

[30]  C. Varcoe,et al.  Introduction: Beyond gender matters , 2008 .

[31]  A. Marcee.  Expanded access to Phase II clinical trials in oncology: a step toward increasing scientific validity and compassion. , 2008, Food and drug law journal.

[32]  A. Hammarström.  A tool for developing gender research in medicine: examples from the medical literature on work life. , 2007, Gender medicine.

[33]  A. Lippman.  The Inclusion of Women in Clinical Trials: Are We Asking the Right Questions? , 2006 .

[34]  Van Gosse,et al.  Boston Women’s Health Book Collective , 2005 .

[35]  Joy L. Johnson,et al.  International Journal for Equity in Health Open Access Better Science with Sex and Gender: Facilitating the Use of a Sex and Gender-based Analysis in Health Research Sex and Gender in Health Research , 2022 .